(co-hosted by Stanford, UCSF, Intermountain Healthcare) on January 23-25, 2017.
Members listed at the end of the paper. Published Online: 30 October 2015
The NBDA inaugural workshop is Workshop I in a series that will, over the next several months, bring together groups of experts from all sectors to specifically identify the level of interests standards needed to build a rational (and predictable) biomarker development pipeline. The NBDA, which is hosted by Arizona State University (ASU), currently consists of three founding partners, ASU, the Critical Path Institute (C-Path) and the International Genome Consortium (IGC). Workshop I, is scheduled for December 13 -14, 2012, at the Camelback Inn, Scottsdale, AZ
"Among featured speakers will be ASU professors George Poste and Edward Prescott.
Poste is an ASU Regents’ Professor, chief scientist of the university’s Complex Adaptive Systems Initiative and the Del E. Webb Chair in Health Innovation. He’ll focus on the role of analytical and computational systems in meeting challenges and creating opportunities in personalized medicine."
George Poste, David P. Carbone, David R. Parkinson, et al.
Clin Cancer Res 2012;18:1515-1523. Published online March 14, 2012.
Abstract: Molecular diagnostics are becoming increasingly important in clinical research to stratify or identify molecularly profiled patient cohorts for targeted therapies, to modify the dose of a therapeutic, and to assess early response to therapy or monitor patients. Molecular diagnostics can also be used to identify the pharmacogenetic risk of adverse drug reactions.
Future Tense forum – "How to Save America's Knowledge Enterprise from Tight Budgets, Primitive Myths & the Shadow of Albert Einstein" – scheduled for 12 to 5:30 p.m., May 21, at the New America Foundation in Washington, D.C.
Sarewitz joins other scholars, including George Poste, chief scientist of ASU's Complex Adaptive Systems Initiative, and founder and former director of the Biodesign Institute at ASU; Jonathan Koppell, director of ASU's School of Public Affairs and dean of the College of Public Programs; and ASU President Michael Crow.
Sooner than we think, we will have access to our own genetic codes. Are we ready to join the DNA generation?
Two ASU researchers, Gary Marchant and George Poste, will tackle legal and ethical dilemmas surrounding personalized medicine on “Arizona Horizon” at 5:30 p.m., March 28, on Eight, Arizona PBS. That same evening, Eight will premiere the new NOVA program “Cracking Your Genetic Code” at 8 p.m.
Kenneth H. Buetow, a human geneticist and former director of the Center for Biomedical Informatics and Information Technology at the National Cancer Institute, is joining Arizona State University as director of Computational Sciences and Informatics in the Complex Adaptive Systems Initiative. He will hold the rank of full professor in the School of Life Sciences in ASU’s College of Liberal Arts and Sciences. His appointment is effective March 5.
The Complex Adaptive Systems Initiative (CASI) was established in 2009 to leverage ASU’s interdisciplinary research strengths on complex global challenges where an integrated cross-disciplinary effort is essential. The establishment of the Computational Sciences and Informatics program in CASI will represent a major foundational resource in this effort by developing world class computing and modeling expertise and capabilities with breadth and depth in key areas such as agent base modeling, visualization, algorithm development and expert systems in healthcare, the environment and national security.
Dr. Poste gave a presentation on The Impact of the Life Sciences on National Security. Dr. Poste made the case that the national security landscape is changing because of vulnerabilities posed both by new life science technologies and by military applications of life technologies.
In an invited commentary published in the January 13 issue of Nature, George Poste, Chief Scientist for ASU’s Complex Adaptive Systems Initiative, makes a case for replacing the current patchwork of fragmented research on disease-associated biomarkers with a coordinated 'big science' approach. Biomarkers are molecular changes in body tissues and fluids that signal the presence of a disease.
Dr. Poste argues that biomarkers have the potential to dramatically improve the ability of physicians to diagnose disease and tailor treatments to individuals— but that current research is not delivering on this potential. He outlines key changes needed to advance this important area of medical research.